Genesis Drug Discovery & Development, the contract research organisation unit of Genesis Biotechnology Group, announced on Thursday that it has named Anthony Rohr as its new chief operating officer.

Rohr is to offer operational leadership, oversight, and coordination across all Genesis Drug Discovery & Development member companies in this role. He has served as business development manager for GBG, chief executive officer of PharmOptima, and senior director of operations at MPI Research, Inc. He has 20 years of experience in the pharmaceutical, biotechnology, and CRO industries.